Oh, more “Science”(which must be pronounced in a hushed, reverent tone). It may be the Daily Kos, but out of several articles I saw, it’s the best.
Two decades of Alzheimer’s research may be based on deliberate fraud that has cost millions of lives
Last month, drug company Genentech reported on the first clinical trials of the drug crenezumab, a drug targeting amyloid proteins that form sticky plaques in the brains of Alzheimer’s disease patients. The drug had been particularly effective in animal models, and the trial results were eagerly awaited as one of the most promising treatments in years. It did not work. “Crenezumab did not slow or prevent cognitive decline” in people with a predisposition toward Alzheimer’s.
Over the last two decades, Alzheimer’s drugs have been notable mostly for having a 99% failure rate in human trials. It’s not unusual for drugs that are effective in vitro and in animal models to turn out to be less than successful when used in humans, but Alzheimer’s has a record that makes the batting average in other areas look like Hall of Fame material.
And now we have a good idea of why. Because it looks like the original paper that established the amyloid plaque model as the foundation of Alzheimer’s research over the last 16 years might not just be wrong, but a deliberate fraud.
[more at link]
“Medicine” and “Doctors” - also in hushed reverent tone...
FDA Warns Puberty Blockers May Cause Vision Loss In Children
The use of puberty blockers may result in vision loss. The FDA issues a warning about idiopathic intracranial hypertension, also known as pseudotumor cerebri in children.
https://greatgameindia.com/puberty-blockers-vision-loss/
Gonadotropin-releasing hormone (GnRH) agonists, often known as puberty blockers, now include a warning from the U.S. Food and Drug Administration that the drugs may result in a range of symptoms in children, including headaches, pressure building around the brain, and vision loss.
[More at link]
